Clinical Trial Update: Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol [Phase 3]

View source ↗

Summary

An open-label extension study of MPC-7869 for Alzheimer's disease patients who previously participated in MPC-7869 trials has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MPC-7869

Snippet

Sponsor: Myrexis Inc. | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED